Etrasimod was effective and well tolerated as an induction and maintenance therapy
in patients with moderately to severely active ulcerative colitis. Etrasimod is a
treatment option with a unique combination of attributes that might address the persistent
unmet needs of patients with ulcerative colitis.
Share this article
Share this article
HOUSTON, Jan. 19, 2021 /PRNewswire/ Pharm-Olam, a global mid-sized clinical research organization (CRO), has been selected by the U.S. Department of Defense s (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to lead and provide full service clinical trial support of the Adalimumab COVID Therapeutic Trial. The JPEO-CBRND awarded Pharm-Olam a $36.3 million agreement to execute an adaptive, outpatient Phase II/III clinical trial of the monoclonal antibody, where adalimumab will be tested as a treatment against the inflammatory response and associated complications brought on by COVID-19.
(PRNewsfoto/Pharm-Olam, LLC)
Pharm-Olam has been selected by the U.S. Department of Defense as CRO to support the Adalimumab COVID Therapeutic Trial.